Table 4A.
Predictors of virological rebound in patients treated with lamivudine (LAM). (A) Comparison of HBeAg-positive patients with or without virological rebound by univariate analysis.
| Virological rebound | No | Yes | P-values |
|---|---|---|---|
| Number | 38 | 23 | |
| Age (years) | 42 ± 11 | 49 ± 11 | 0.019 |
| Gender (male) | 30 | 17 | N.S. |
| HBV DNA (log IU/mL) | 6.9 ± 1.2 | 6.8 ± 0.9 | N.S. |
| ALT (IU/L) | 379 ± 377 | 196 ± 205 | 0.037 |
| US: Cirrhosis (+) | 7 | 9 | N.S. |
| Periods to undetectable HBV DNA (months) | 20.6 ± 29.1 | 4.1 ± 3.1 | 0.009 |
Data are expressed as mean ± SD. P-values, P-values between patients with or without virological rebound groups; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; US, ultrasound findings; N.S., no statistically significant difference.